More than a third of women who suffer from diabetes during pregnancy develop type 2 diabetes within five years and those most at risk can be predicted from their blood glucose levels at diagnosis, according to a study published in the June issue of the Postgraduate Medical Journal.
Poor glucose control is often attributed to clinical inertia: the recognition of a problem by the physician, but failing to act.
Researchers at the University of Pennsylvania School of Medicine have discovered a potential new target for treating type 2 diabetes, according to a new study that appeared online this week in Nature. The target is a protein, along with its molecular partner, that regulates fat metabolism.
The U.S. Food and Drug Administration today approved a device that measures glucose levels continuously for up to seven days in people with diabetes.
Typified by high blood pressure, weight gain around the waist and problems regulating blood sugar, metabolic syndrome may also be associated with compromised heart structure and function, according to a paper published in the online open access journal BMC Cardiovascular Disorders.
On June 5, 2007, the New England Journal of Medicine published results of an interim analysis of the cardiovascular safety trial of rosiglitazone (brand name, Avandia).
Abbott announced that it received European CE Mark (Conformit? Europ?ene) approval for the FreeStyle Navigator? Continuous Glucose Monitoring System for people with diabetes.
Low levels of testosterone may increase the long-term risk of death in men over 50 years old, according to researchers with the Department of Family and Preventive Medicine at the University of California, San Diego School of Medicine.
The following is GlaxoSmithKline?s [NYSE:GSK] response to editorials written in the New England Journal of Medicine (NEJM) regarding Avandia? for the treatment of type 2 diabetes.
Normally sedentary breast cancer survivors who completed an exercise program reduced the levels of insulin in their blood, revealing a likely link between physical activity and better outcomes, researchers from Dana-Farber Cancer Institute in Boston reported at the annual meeting of the American Society of Clinical Oncology in Chicago.